IVF Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
INVO Fertility, Inc. had $6.8M of revenue in fiscal 2025, up 4.7% on the year before. Over five years, revenue changed +45.8% a year on average.
Last close Β· Oct 23, 2026
$0.57
7.0%Hi! I read INVO Fertility, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+4.7%
Only a little. Sales grew 4.7% last year.
Does it make a profit?
β340.9%
No. It lost money last year.
Does profit turn into cash?
β103.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· INVO Fertility, Inc. had $6.8M of revenue in fiscal 2025, up 4.7% on the year before. Over five years, revenue changed +45.8% a year on average. Its operating margin was β105.8%, down 4.3Β pts: of every 100 in sales, about β106 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· INVO Fertility, Inc. lost $23.3M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$7.1M in fiscal 2025, β103.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $0.0M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 3, 2025 | Matthew K SzotDirector | Sold | 4 | $1.52 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· INVO Fertility, Inc. has $1.2M more cash than debt.
Cash, debt and the ratios that show how comfortably INVO Fertility, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.7M | $0.1M | $0.2M | $0.6M | $2.1M |
| Debt incl. finance leases | β | β | β | $7.5M | $0.9M |
| Debt / equity | β | β | β | 0.6x | 0.1x |
| Interest coverage | β4.1x | β178.9x | β7.3x | β6.3x | β5.6x |
| Current ratio | 5.4x | 0.2x | 0.2x | 0.1x | 0.3x |
| Quick ratio | 5.1x | 0.1x | 0.1x | 0.1x | 0.2x |
| Total assets | $10.0M | $3.7M | $18.5M | $46.1M | $20.2M |
| Total liabilities | $2.7M | $4.7M | $17.6M | $26.0M | $13.0M |
| Shareholders' equity | $7.3M | β$1.0M | $0.9M | $12.6M | $7.2M |
| Net debt (β = net cash) | β | β | β | $6.8M | β$1.2M |
KIRA Β· Its return on capital was β94.7%: every 100 invested in the business earned about β95 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· INVO Fertility, Inc. passes 5 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 3 / 8 | 7 / 8 | 4 / 8 | 5 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 5 / 9 |
| Accruals ratio | β629.1% | β188.5% | β464.3% | β275.0% | β56.1% | β6.0% | β62.6% | β29.5% | β19.5% | β49.2% |
| Altman Z'' | β358.54 | β365.79 | β138.07 | β50.62 | β6.88 | β9.96 | β68.02 | β14.98 | β7.59 | β19.01 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.1M | $0.3M | $0.5M | $1.5M | $1.0M | $4.2M | $0.8M | $3.0M | $6.5M | $6.8M |
| Gross profit | $0.0M | $0.2M | $0.4M | $1.3M | $0.9M | $4.0M | $0.5M | $1.0M | $2.8M | $6.8M |
| Research and development | β | β | β | $0.0M | $0.4M | $0.2M | $0.5M | $0.2M | $0.0M | β |
| Operating income | β$2.1M | β$0.6M | β$2.6M | β$1.8M | β$5.5M | β$5.2M | β$10.6M | β$6.8M | β$6.6M | β$7.2M |
| Interest expense | $0.0M | $0.0M | $0.4M | $0.4M | $2.8M | $1.3M | $0.1M | $0.9M | $1.1M | $1.3M |
| Pretax income | β$2.1M | β$0.7M | β$3.1M | β$2.2M | β$8.3M | β$6.7M | β$10.9M | β$8.0M | β$7.6M | β$5.5M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | β$0.2M |
| Net income | β$2.1M | β$0.7M | β$3.1M | β$2.2M | β$8.3M | β$6.7M | β$10.9M | β$8.0M | β$9.3M | β$23.3M |
| Net income to common | β$2.1M | β$0.7M | β$3.1M | β$2.2M | β$8.3M | β | β | β$8.0M | β$9.5M | β$25.1M |
| Diluted EPS | β$0.02 | $0.00 | β$0.02 | β$0.45 | β$1.52 | β$0.63 | β$17.97 | β$67.37 | β$3,782.65 | β$214.64 |
| Diluted shares | 0.14B | 0.14B | 0.15B | 0.00B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$0.3M | β$0.2M | β$0.7M | $1.4M | β$4.8M | β$6.0M | β$6.6M | β$4.8M | β$3.0M | β$7.0M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.4M | $0.0M | $0.4M | $0.2M | $0.0M |
| Free cash flow | β$0.3M | β$0.2M | β$0.7M | $1.3M | β$4.8M | β$6.4M | β$6.6M | β$5.2M | β$3.2M | β$7.1M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.2M | $0.9M | $0.7M |
| Stock-based compensation | β | β | $0.0M | $0.1M | $1.1M | $1.5M | $1.6M | β | β | $0.2M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.2M | $0.0M | $0.2M | $1.2M | $10.1M | $5.7M | $0.1M | $0.2M | $0.6M | $2.1M |
| Total debt | β | β | β | β | β | β | β | β | $7.5M | $0.9M |
| Current assets | $0.3M | $0.2M | $0.7M | $1.5M | $10.5M | $6.3M | $0.6M | $1.3M | $1.3M | $2.8M |
| Current liabilities | $4.8M | $5.1M | $3.5M | $1.5M | $2.3M | $1.2M | $3.3M | $8.0M | $17.9M | $10.3M |
| Inventory | $0.1M | $0.1M | $0.0M | $0.1M | $0.3M | $0.3M | $0.3M | $0.3M | $0.2M | $0.2M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.5M | $0.4M | $0.8M | $0.5M | $0.4M |
| Goodwill | β | β | β | β | β | β | β | $5.9M | $5.9M | $5.9M |
| Intangible assets | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | β | $4.1M | $3.3M | $1.3M |
| Total assets | $0.3M | $0.3M | $0.8M | $1.8M | $10.9M | $10.0M | $3.7M | $18.5M | $46.1M | $20.2M |
| Total liabilities | $4.9M | $5.3M | $3.5M | $5.5M | $5.2M | $2.7M | $4.7M | $17.6M | $26.0M | $13.0M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β | β | β |
| Shareholders' equity | β$4.6M | β$5.0M | β$2.7M | β$3.7M | $5.7M | $7.3M | β$1.0M | $0.9M | $12.6M | $7.2M |
| Margins | ||||||||||
| Gross margin | 70.3% | 81.6% | 81.7% | 90.6% | 91.4% | 96.5% | 59.7% | 34.7% | 43.1% | 99.6% |
| Operating margin | β4,146.2% | β227.0% | β532.8% | β120.8% | β531.7% | β125.4% | β1,292.4% | β224.0% | β101.5% | β105.8% |
| EBITDA margin | β4,142.4% | β226.0% | β531.7% | β120.1% | β530.5% | β124.7% | β1,283.0% | β217.4% | β87.4% | β95.9% |
| Net margin | β4,173.5% | β248.9% | β622.2% | β146.4% | β804.7% | β160.0% | β1,324.8% | β266.0% | β141.7% | β340.9% |
| FCF margin | β667.2% | β64.3% | β136.0% | 88.2% | β465.1% | β154.9% | β804.4% | β172.1% | β48.3% | β103.2% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | β | β26.9% | β94.7% |
| Return on capital employed | 47.0% | 13.2% | 96.7% | β607.4% | β63.7% | β59.1% | β2,858.1% | β64.4% | β23.5% | β73.2% |
| Return on equity | β | β | β | β | β822.6% | β102.0% | β344.0% | β | β137.4% | β235.5% |
| Return on assets | β742.2% | β254.1% | β589.5% | β168.5% | β131.0% | β63.6% | β159.0% | β72.3% | β28.7% | β70.4% |
| Return on tangible equity | β | β | β | β | β147.8% | β92.7% | β | β | β277.3% | β125,025.9% |
| Growth | ||||||||||
| Revenue growth | β | 454.2% | 75.3% | 199.4% | β29.9% | 301.1% | β80.2% | 267.4% | 116.2% | 4.7% |
| FCF growth | β | β | β | β | β469.5% | β | β | β | β | β |
| Share count change | β | 1.5% | 4.3% | β96.7% | 13.1% | 93.7% | β94.3% | β80.3% | β97.9% | 4,584.0% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | β | β | β | 0.6x | 0.1x |
| Interest coverage | β152.9x | β30.6x | β6.0x | β4.6x | β1.9x | β4.1x | β178.9x | β7.3x | β6.3x | β5.6x |
| Current ratio | 0.1x | 0.0x | 0.2x | 1.0x | 4.6x | 5.4x | 0.2x | 0.2x | 0.1x | 0.3x |
| Quick ratio | 0.0x | 0.0x | 0.2x | 1.0x | 4.5x | 5.1x | 0.1x | 0.1x | 0.1x | 0.2x |
| Capital allocation | ||||||||||
| Capex / revenue | 30.8% | 0.0% | 3.9% | 4.4% | 4.8% | 10.0% | 1.3% | 14.7% | 2.8% | 0.6% |
| Stock comp / revenue | β | β | 0.0% | 4.7% | 110.0% | 37.1% | 196.6% | β | β | 2.4% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 3.0 | 7.0 | 4.0 | 5.0 | 2.0 | 3.0 | 4.0 | 5.0 |
| Altman Z'' | β358.5 | β365.8 | β138.1 | β50.6 | β6.9 | β10.0 | β68.0 | β15.0 | β7.6 | β19.0 |
| Accruals ratio | β629.1% | β188.5% | β464.3% | β275.0% | β56.1% | β6.0% | β62.6% | β29.5% | β19.5% | β49.2% |
Source: SEC EDGAR XBRL filings (CIK 0001417926). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
